Cervical carcinoma

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

This study tests whether adding a glutaminase inhibitor (telaglenastat) to standard chemoradiation helps people with advanced cervical cancer live longer without the disease getting worse. About 42 adults with stage III–IVA cervical cancer will receive the drug alongside standard…

This study looks at whether giving women living with HIV the option to collect their own HPV test samples at home or in their community, with help from health workers, increases how many get screened for cervical cancer. About 17,700 women will take part across multiple clinics. …

This trial compares an experimental drug called JSKN033 with standard chemotherapy in people whose cervical cancer has returned or spread and no longer responds to platinum-based chemotherapy or PD-1/L1 inhibitors. The study includes about 368 adults with recurrent or metastatic …

This study tests whether a self-applied cream (5-fluorouracil) after a heat procedure (thermal ablation) can clear HPV better than a placebo cream in 140 women with HIV in Kenya. Participants will use the cream every two weeks for 24 weeks and be followed for 48 weeks total. The …

This phase 2 trial is testing whether adding relacorilant—a drug that blocks a stress-related hormone—to the chemotherapy nab-paclitaxel can shrink tumors in people with recurrent or metastatic cervical cancer. Participants have already tried platinum-based chemo and immunotherap…

This study looks at how well a combination of two drugs, iparomlimab and tuvonralimab (called QL1706), works for people with recurrent or metastatic cervical cancer that has worsened after platinum-based chemotherapy. Researchers will compare outcomes of those receiving QL1706 to…

This Phase 2 trial tests a combination of three drugs—camrelizumab, famitinib, and standard chemotherapy—in 54 women with recurrent or metastatic cervical cancer that cannot be treated with surgery or radiation. The goal is to see if the combo shrinks tumors and controls the dise…

This phase II trial is testing whether adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery can help shrink tumors in women with early-stage cervical cancer (stages IB1-IB3). About 50 participants will receive the combination, then undergo conservative su…

This study tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to chemotherapy before standard chemoradiation can help people with locally advanced cervical cancer live longer without the disease getting worse. About 486 adults aged 18-75 with stage III-IV…

This study tests two experimental drugs, MRG003 and QL1706, together in people with cervical cancer that has returned or spread and no longer responds to standard chemotherapy. About 41 adults will receive the combination to see if it shrinks tumors. The goal is to control the di…

This phase II trial tests a drug called cadonilimab combined with radiation therapy for women with advanced cervical cancer who cannot receive standard chemotherapy due to age or health issues. The study will enroll 45 participants and measure how many have a complete response (n…

This study tests a new, custom-made 3D-printed applicator for delivering high-dose radiation (brachytherapy) to treat locally advanced cervical cancer. About 25 participants will receive the treatment to see if the device works safely and as planned. The goal is to improve how ra…

This Phase 3 trial tests whether a combination of two drugs, WX390 and toripalimab, can help people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemotherapy. About 440 participants will be randomly assigned to receive either the new combi…

This phase II trial tests a combination of two drugs—Utidelone and Toripalimab—in people with recurrent or metastatic cervical cancer that has stopped responding to standard treatments. All 32 participants will receive the same treatment, and doctors will monitor tumor shrinkage …

This study will observe 1,300 patients with advanced or recurrent cervical cancer who are treated with camrelizumab, famitinib, or combinations of these drugs. The goal is to see how safe and effective these treatments are in real-world settings. Patients are placed into one of s…

This study compares two surgical methods for early-stage cervical cancer (IB2-IIA1). One is traditional open surgery, and the other is a minimally invasive approach using a stapler to prevent cancer cells from spreading. About 494 participants will be followed for 4.5 years to se…

This phase 2 trial tests whether adding the immunotherapy drug ivonescimab to chemotherapy before standard chemoradiation can improve outcomes for women with high-risk, locally advanced cervical cancer. About 42 participants will receive two cycles of the combination, then procee…

This study tests three different doses of the drug famitinib combined with camrelizumab in 120 people with recurrent or metastatic cervical cancer that cannot be cured by standard treatments. The goal is to find a dose that keeps the cancer under control while causing fewer sever…

This study looks at whether a single, image-guided radiation implant can control advanced cervical cancer as well as the usual multiple implants. About 400 women from six French hospitals who had this single-implant treatment between 2014 and 2024 will have their medical records …

This Phase 2 trial compares two approaches for locally advanced cervical cancer: standard chemoradiotherapy versus a newer strategy of chemotherapy plus immunotherapy (sintilimab) before surgery. The study will enroll 180 people and track how long they live without the cancer get…

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy, with or without a blood-vessel-blocking drug, in 25 women whose recurrent or metastatic cervical cancer has worsened after prior PD-1/PD-L1 treatment. The goal is to see ho…

This phase 2 trial tests a combination of three drugs—disitamab vedotin, iparomlimab, and tuvonralimab—in 33 women with HER2-expressing recurrent cervical cancer that has progressed after first-line treatment. The goal is to see if the combo can shrink tumors or slow the disease.…

This study tests whether community health workers can help women in rural North Carolina use at-home HPV self-collection kits to screen for cervical cancer. About 112 women aged 30-64 who haven't been screened recently will receive kits through local organizations. The goal is to…

This pilot study aims to see if offering self-collection kits for cervical cancer screening and HPV vaccination in emergency departments can reach women who have limited healthcare access. Researchers will enroll 100 women aged 18-65 and track how many participate and complete th…

This study in Zimbabwe will screen women of childbearing age and high school students for HPV and Hepatitis B, then offer vaccines to those who are eligible. It also includes cognitive behavioral therapy for mental health issues. The goal is to see if this combined approach can p…

This study tests whether alendronate, a drug used for osteoporosis, can prevent pelvic fractures in cervical cancer patients who have had chemotherapy and radiation. About 65 adults with non-metastatic cervical cancer will receive alendronate to see if it strengthens bones and re…

This trial tests whether protecting the anal canal during pelvic radiation can reduce hemorrhoid-related symptoms like pain, bleeding, and discomfort in cervical cancer patients. 300 women who had a hysterectomy and need radiation will be randomly assigned to standard radiation o…

This study tests better ways to screen and treat cervical cancer in women living with HIV in Kenya, who face a much higher risk. Researchers will use HPV self-testing, care navigators, and a mobile app to help more women get diagnosed and treated. The goal is to find strategies t…

This study is testing whether a simple blood test that detects HPV DNA from tumor cells can help predict if cervical cancer will come back after surgery. Researchers will collect blood samples before surgery and at two time points afterward from about 580 patients with early-stag…

This study looks at whether pieces of tumor DNA and HPV DNA circulating in the blood can predict if cervical cancer will return after successful first-line treatment. Researchers will collect blood samples over time from 60 patients whose cancer has gone into complete remission. …

This study will develop and test a free, cloud-based platform to educate women aged 18-45 with early-stage gynecologic cancer about fertility preservation options. Researchers will compare awareness, knowledge, and attitudes between a group using the platform and a group receivin…

This study will follow 100 people with advanced cervical cancer who are getting radiation and chemo. Researchers want to see if checking for HPV and other markers in the blood and cervix can better predict if the cancer will come back. The goal is to find recurrences earlier and …

This study looks at how well patients do after surgery that removes both advanced gynecologic cancers and the major blood vessels they have grown into. Researchers will track 130 participants for up to 5 years to see survival rates and how long it takes for the cancer to return. …

This study looks at whether using CT scans instead of MRI for planning brachytherapy (internal radiation) can work just as well for locally advanced cervical cancer. About 1,200 participants will receive standard treatment, and researchers will track tumor control and side effect…